| Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor … F Ciardiello, R Caputo, V Damiano, R Caputo, T Troiani, D Vitagliano, ... Clinical Cancer Research 9 (4), 1546-1556, 2003 | 459 | 2003 |
| Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) C Bianco, G Tortora, R Bianco, R Caputo, BM Veneziani, R Caputo, ... Clinical cancer research 8 (10), 3250-3258, 2002 | 337 | 2002 |
| Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative … G Tortora, R Caputo, V Damiano, D Melisi, R Bianco, G Fontanini, ... Clinical Cancer Research 9 (4), 1566-1572, 2003 | 193 | 2003 |
| Epithelial-mesenchymal transition in prostate cancer: an overview M Montanari, S Rossetti, C Cavaliere, C D'Aniello, MG Malzone, ... Oncotarget 8 (21), 35376, 2017 | 190 | 2017 |
| Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells E Crescenzi, L Varriale, M Iovino, A Chiaviello, BM Veneziani, G Palumbo Molecular cancer therapeutics 3 (5), 537-544, 2004 | 161 | 2004 |
| Adenosine 3′, 5′-monophosphate mediates both the mitogenic effect of thyrotropin and its ability to amplify the response to insulin-like growth factor I in FRTL5 cells D Tramontano, AC MOSES, B MARIA VENEZIANI, SH INGBAR Endocrinology 122 (1), 127-132, 1988 | 154 | 1988 |
| Micrornas in prostate cancer: an overview D Vanacore, M Boccellino, S Rossetti, C Cavaliere, C D'Aniello, ... Oncotarget 8 (30), 50240, 2017 | 139 | 2017 |
| Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models R Rosa, R Marciano, U Malapelle, L Formisano, L Nappi, C D'Amato, ... Clinical cancer research 19 (1), 138-147, 2013 | 117 | 2013 |
| The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models V D'amato, R Rosa, C D'amato, L Formisano, R Marciano, L Nappi, ... British journal of cancer 110 (12), 2887-2895, 2014 | 98 | 2014 |
| Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small … E Crescenzi, A Chiaviello, G Canti, E Reddi, BM Veneziani, G Palumbo Molecular cancer therapeutics 5 (3), 776-785, 2006 | 97 | 2006 |
| Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers C Di Mauro, R Rosa, V D'Amato, P Ciciola, A Servetto, R Marciano, ... British journal of cancer 116 (11), 1425-1435, 2017 | 87 | 2017 |
| Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors CD Mauro, A Pesapane, L Formisano, R Rosa, V D’Amato, P Ciciola, ... Scientific reports 7 (1), 9388, 2017 | 80 | 2017 |
| Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases MP Morelli, T Cascone, T Troiani, C Tuccillo, R Bianco, N Normanno, ... Journal of cellular physiology 208 (2), 344-353, 2006 | 79 | 2006 |
| Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and … G Tortora, R Caputo, V Damiano, R Caputo, T Troiani, BM Veneziani, ... Clinical cancer research 9 (2), 866-871, 2003 | 79 | 2003 |
| Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models L Formisano, L Nappi, R Rosa, R Marciano, C D’Amato, V D’Amato, ... Breast Cancer Research 16, 1-15, 2014 | 78 | 2014 |
| Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis M Giuliano, S Herrera, P Christiny, C Shaw, CJ Creighton, T Mitchell, ... Breast cancer research 17, 1-9, 2015 | 66 | 2015 |
| Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences V Quagliariello, S Rossetti, C Cavaliere, R Di Palo, E Lamantia, ... Oncotarget 8 (18), 30606, 2017 | 65* | 2017 |
| Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells C D’Amato, R Rosa, R Marciano, V D’Amato, L Formisano, L Nappi, ... British journal of cancer 111 (6), 1168-1179, 2014 | 62 | 2014 |
| Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative … G Tortora, R Caputo, V Damiano, G Fontanini, D Melisi, BM Veneziani, ... Clinical cancer research 7 (12), 4156-4163, 2001 | 61 | 2001 |
| Independent and interactive effects of tetradecanoyl phorbol acetate on growth and differentiated functions of FRTL5 cells A LOMBARDI, B MARIA VENEZIANI, D Tramontano, SH INGBAR Endocrinology 123 (3), 1544-1552, 1988 | 58 | 1988 |
